Cargando…

1301. Breakthrough Invasive Fungal Infections based on CYP2C19 Levels in Patients Who were on Voriconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) undergoing Induction Chemotherapy

BACKGROUND: Voriconazole (Vori) is often used for prophylactic anti-fungal therapy in induction chemotherapy for Acute Myeloid Leukemia (AML) patients due to predictable absorption and an extended spectrum antifungal activity. Vori is metabolized predominately by CYP2C19 to metabolites with less ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singam, Hareesh v, Pasikhova, Yanina, Quilitz, Rod, Greene, John N, Baluch, Aliyah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777358/ http://dx.doi.org/10.1093/ofid/ofaa439.1484

Ejemplares similares

742. Breakthrough Invasive Fungal Infections with Isavuconazonium Sulfate versus Voriconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia (AML) who Received Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

483. Use of Terbinafine in Combination with Other Systemic Anti-fungal Agents As Treatment for Invasive Mold Infections. Experience from A National Cancer Institute Designated Cancer Center.
por: Ajayi, Eloho, et al.
Publicado: (2022)

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
por: Al-Bahou, Amanda, et al.
Publicado: (2021)

Early Antimicrobial De-escalation and Stewardship in Adult Hematopoietic Stem Cell Transplantation Recipients: Retrospective Review
por: Snyder, Matthew, et al.
Publicado: (2017)

Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients
por: Snyder, Matthew, et al.
Publicado: (2021)

Intestinal Coccidian Infections in Cancer Patients: A Case Series
por: Einhorn, Nathan, et al.
Publicado: (2023)

Disseminated Toxoplasmosis in an Allogeneic Hematopoietic Stem Cell Transplant Recipient: A Case Report and Review of the Current Literature
por: Baluch, Aliyah, et al.
Publicado: (2022)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
por: Pasikhova, Yanina, et al.
Publicado: (2022)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
por: Hall, Victoria G, et al.
Publicado: (2023)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

971. Breakthrough Invasive Fungal Infections (IFI) in Acute Leukemia (AL) Patients Receiving Antifungal Prophylaxis
por: Wasylyshyn, Anastasia, et al.
Publicado: (2018)

974. Real World Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels
por: Pasikhova, Yanina, et al.
Publicado: (2023)

2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes
por: Mourad, Ahmad, et al.
Publicado: (2019)

microRNA-1301-mediated inhibition of tumorigenesis
por: FANG, LIN, et al.
Publicado: (2011)

1301. Evaluation of the Rates of HIV Post-Exposure Prophylaxis Completion After the Implementation of an Automated Referral System in the Emergency Department
por: Schwarz, Erika Reategui, et al.
Publicado: (2018)

Antifungal Prophylaxis
por: Johnson, Douglas Clark, et al.
Publicado: (2021)

Safety and Outcomes With Combination Therapy With Sarilumab and Baricitinib for Severe COVID-19 Respiratory Infection in Cancer Patients
por: Velez, Ana Paula, et al.
Publicado: (2023)

1220. Comparing Breakthrough Fungal Infections in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients Receiving Prophylaxis with Different Azoles
por: Chen, Catherine, et al.
Publicado: (2023)

Synthesis of Isomeric and Potent Impurities of the Triazole-Based Antifungal Drug Voriconazole
por: Sundaram, Dhanraj T. S. S., et al.
Publicado: (2015)

Antifungal management in ICU: careful follow-up of voriconazole prescription needed!
por: Reizine, Florian, et al.
Publicado: (2023)

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
por: Grau, Santiago, et al.
Publicado: (2016)

Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study
por: Rinaldi, Matteo, et al.
Publicado: (2021)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy
por: L. Kandaurava, Sviatlana, et al.
Publicado: (2020)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

La propiedad territorial en México, 1301-1810
por: Rivera Marín de Iturbe, Guadalupe
Publicado: (1983)

Aberrant Expression of miR-1301 in Human Cancer
por: Zhong, Chenming, et al.
Publicado: (2022)

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2020)

Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report
por: Akers, Kevin S, et al.
Publicado: (2015)

Molecular and cellular responses of the pathogenic fungus Lomentospora prolificans to the antifungal drug voriconazole
por: Pellon, Aize, et al.
Publicado: (2017)

Fabrication and Evaluation of Voriconazole Loaded Transethosomal Gel for Enhanced Antifungal and Antileishmanial Activity
por: Farooq, Mudassir, et al.
Publicado: (2022)

Comparison of the antifungal effect of voriconazole and fluconazole on oral candidiasis before and during radiotherapy
por: Golestannejad, Zahra, et al.
Publicado: (2022)

Reply: Antifungal Prophylaxis
por: Pennington, Kelly M., et al.
Publicado: (2021)

Paecilomyces Pneumonia Despite Voriconazole Prophylaxis: A Case Report and Literature Review
por: Asif, Abuzar A, et al.
Publicado: (2021)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dcfk2cc9djpf9g2flhsjd3bgr2